Search our Database of Scientific Publications and Authors

I’m looking for a

    564 results match your criteria Cardiovascular Therapeutics[Journal]

    1 OF 12

    Tetrahydrobiopterin (BH4 ): Targeting endothelial Nitric Oxide Synthase as a potential therapy for Pulmonary Hypertension.
    Cardiovasc Ther 2017 Nov 19. Epub 2017 Nov 19.
    Department of Internal Medicine B, Ziv Medical Center, Faculty of Medicine in the Galilee, Bar-Ilan University, Henrietta Szold st. 8, POB 1589, Safed, Israel.
    Purpose: Pulmonary Hypertension (PH) is complex disease which is associated with endothelial and cardiac dysfunction. Tetrahydrobiopterin (BH4 ) regulates endothelial nitric oxide synthase (eNOS) to produce nitric oxide rather than superoxide which maintains normal endothelial and cardiac function. This study explores the therapeutic potential of BH4 in experimental PH. Read More

    The APEX Trial: Effects of Allopurinol on Exercise Capacity, Coronary and Peripheral Endothelial Function and Natriuretic Peptides in Patients with Cardiac Syndrome X.
    Cardiovasc Ther 2017 Oct 28. Epub 2017 Oct 28.
    Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical, School, University of Dundee, DD1 9SY, United Kingdom.
    The role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has recently been recognised. Allopurinol has previously been shown to improve endothelial dysfunction, reduce oxidative stress burden and improve myocardial efficiency. In this 'proof of concept' study, we investigated the effect of allopurinol on exercise capacity, coronary and peripheral endothelial function, and serum B-type natriuretic peptide (BNP: a marker of cardiac function and myocardial ischaemia) in patients with cardiac syndrome X. Read More

    The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Cardiovasc Ther 2017 Oct 27. Epub 2017 Oct 27.
    Pfizer Inc, South San Francisco and San Diego, CA, USA.
    Aims: Three single-dose and one multiple-dose phase I studies were conducted in subjects with primary hypercholesterolemia to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

    Methods: The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were: 1) ascending, single, intravenous (IV) bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg) or placebo (N=48; baseline low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL); 2) single, IV bococizumab (0. Read More

    Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2 DS2 VASc 1 or 2): A treatment dilemma.
    Cardiovasc Ther 2017 Oct 27. Epub 2017 Oct 27.
    Department of Cardiac, Thoracic and Vascular Sciences, Cardiology Clinic, University of Padua, Padua, Italy.
    Introduction: The issue of anticoagulation in individuals with nonvalvular atrial fibrillation (NVAF) and 1 non-gender-related (NGR) risk factor is subject to debate. The reported risk of stroke in untreated individuals is not uniform, and the rate of hemorrhage associated with anticoagulation in this group of individuals is not well defined. To this end, we assessed the rate of stroke and major hemorrhage in individuals treated with warfarin. Read More

    Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Cardiovasc Ther 2017 Oct 23. Epub 2017 Oct 23.
    Pfizer Inc, South San Francisco and San Diego, CA, USA.
    Aims: Two multiple-dose phase II studies were conducted in subjects with primary hypercholesterolemia to evaluate the LDL-C lowering efficacy, safety, and tolerability of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

    Methods: The results from the two phase II, double-blinded, randomized, placebo-controlled, multicenter studies conducted in the USA and Canada were combined. In Study 1, 90 subjects with LDL-C ≥100 mg/dL received intravenous (IV) placebo or bococizumab 0. Read More

    Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
    Cardiovasc Ther 2017 Dec 4;35(6). Epub 2017 Oct 4.
    Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
    Aim: The influence of short-term add-on ezetimibe to simvastatin treatment on expression of adipokines and inflammatory markers was investigated in diabetic and nondiabetic patients with hypercholesterolemia.

    Method: Hypercholesterolemic nondiabetic (HC, n = 37) and diabetic (DM, n = 47) patients were treated with simvastatin (SV, 10 or 20 mg/d/8-wk) and then SV plus ezetimibe (SV + EZ, 10 mg each/d/4 wk). Serum lipids, glycemic profile, and inflammatory markers (hsCRP, adiponectin, resistin, VCAM-1, and ICAM-1) were evaluated before and after the add-on ezetimibe therapy. Read More

    Alamandine reverses hyperhomocysteinemia-induced vascular dysfunction via PKA-dependent mechanisms.
    Cardiovasc Ther 2017 Dec 4;35(6). Epub 2017 Oct 4.
    Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, Vic., Australia.
    Introduction: Hyperhomocysteinemia (HHcy) impairs nitric oxide endothelium-dependent vasodilation, consequently leading to atherosclerosis, a risk factor for cardiovascular disease. Novel treatments for HHcy are necessary.

    Aim: We tested the hypothesis that alamandine, a vasoactive peptide of the renin-angiotensin system (RAS), could reverse HHcy-induced vascular dysfunction through the MrgD receptor and that this is mediated by the protein kinase A (PKA) pathway. Read More

    Oxidized low-density lipoprotein (ox-LDL) promotes cardiac differentiation of bone marrow mesenchymal stem cells via activating ERK1/2 signaling.
    Cardiovasc Ther 2017 Dec 27;35(6). Epub 2017 Sep 27.
    Stem Cell and Biotheraphy Technology Research Center, Xinxiang Medical University, Xinxiang, China.
    Background/aims: The differentiation efficiency of bone marrow mesenchymal stem cells (BM-MSCs) is low in vivo after transplantation. Therefore, it is necessary to look for effective reagents for enhancing cardiac differentiation of BM-MSCs. It has been reported that cardiac differentiation of stem cells depends on the activation of extracellular signal-regulated protein 1/2 (ERK1/2) signaling. Read More

    The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation.
    Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
    Pharmacy, School of Medicine, University of Tasmania, Hobart, Tas, Australia.
    Background: Patients' knowledge regarding their oral anticoagulant (OAC) treatment for stroke prevention in atrial fibrillation (AF), their level of medication adherence, and health literacy are known to affect treatment outcomes. However, contemporary data regarding the relationships between these variables are lacking.

    Objective: To investigate the relationships between anticoagulant knowledge, health literacy, and self-reported adherence in patients taking warfarin and the directly acting oral anticoagulants. Read More

    Long-term survival following the development of heart failure in an elderly hypertensive population.
    Cardiovasc Ther 2017 Dec 3;35(6). Epub 2017 Oct 3.
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia.
    Background: Available data on the prognosis of heart failure (HF) patients are predominantly limited to patients diagnosed at time of hospitalization.

    Aims: To describe the long-term survival of incident HF patients and identify clinical characteristics associated with mortality.

    Methods: The Second Australian National Blood Pressure Study (ANBP2) randomized 6083 hypertensive subjects aged 65-84 years to angiotensin-converting enzyme (ACE) inhibitor or thiazide diuretic-based therapy and followed them for a median of 4. Read More

    The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients.
    Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
    School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand.
    Aim: To investigate the effect of apolipoprotein E (APOE), cholesteryl ester transfer protein (CETP) and proprotein convertase subtilisin kexin type 9 (PCSK9) polymorphisms on the lipid-lowering response to simvastatin therapy in Thai hypercholesterolemic patients.

    Method: Two hundred and twenty-five hypercholesterolemic patients in southern Thailand were enrolled and treated with simvastatin 20 or 40 mg per day for 3 months. Serum lipids were measured before and after the therapy. Read More

    Cognitive impairment and cardiovascular medication use: Results from wave 1 of The Irish Longitudinal Study on Ageing.
    Cardiovasc Ther 2017 Dec 26;35(6). Epub 2017 Sep 26.
    Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
    Aim: To explore the association between cardiovascular medication use and cognitive impairment in adults aged 50 years and over.

    Method: This cross-sectional linked database study involved secondary quantitative analysis of 1903 participants from wave 1 of the Irish Longitudinal Study on Ageing with available pharmacy claims data. Cognitive impairment was assessed using a cut-off of ≤23 on the Montreal Cognitive Assessment. Read More

    Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy.
    Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
    Department of Cardiology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
    Aim: To discuss the pathophysiology of iron metabolism in chronic heart failure (CHF) and the current knowledge of the efficacy of intravenous (IV) iron therapy in patients with CHF and identify points of controversy as well as highlight areas for future research.

    Discussion: Iron deficiency is a recognized complication of many chronic conditions. Numerous studies have reported that iron deficiency is highly prevalent in patients with CHF and is associated with exercise intolerance, reduced quality of life, and increased risk of hospitalization and mortality. Read More

    The vasorelaxant effect of antidiabetic drug nateglinide via activation of voltage-dependent K(+) channels in aortic smooth muscle.
    Cardiovasc Ther 2017 Aug 20. Epub 2017 Aug 20.
    Department of Physiology, Kangwon National University School of Medicine, Chuncheon, South Korea.
    Aims: We investigated the vasorelaxant effect of nateglinide and its related mechanisms using phenylephrine (Phe)-induced precontracted aortic rings.

    Methods: Arterial tone measurement was performed in aortic smooth muscle.

    Results: The application of nateglinide induced vasorelaxation in a concentration-dependent manner. Read More

    Comparison of anticoagulation regimens for pregnant women with prosthetic heart valves: A meta-analysis of prospective studies.
    Cardiovasc Ther 2017 Dec;35(6)
    Qindao University Medical College Affiliated Yantai Yuhuangding Hospital, Yantai, Shandong, China.
    Introduction: Pregnancy is associated with a hypercoagulable state, which makes pregnant women with prosthetic heart valves at high risk of thromboembolism. The proper anticoagulation regimen should take both the maternal protection and the fetal outcomes into consideration. However, no consensus on the present anticoagulation regimen for those women has been reached yet, especially in the first trimester of pregnancy. Read More

    Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease.
    Cardiovasc Ther 2017 Oct;35(5)
    Division of Cardiology, Department of Internal Medicine/Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.
    Introduction And Aims: Endothelial dysfunction and arterial stiffness have a prognostic value on adverse long-term outcomes in coronary artery disease (CAD) patients. We evaluated the efficacy on vascular reactivity of candesartan and analyzed predictors to control the candesartan's effect on vascular reactivity in CAD patients.

    Method: Patients were prospectively enrolled and prescribed candesartan for 6 months. Read More

    Microcatheter balloon pinning technique to facilitate wiring of a left circumflex chronic total occlusion.
    Cardiovasc Ther 2017 Dec;35(6)
    Division of Cardiology, Department of Internal Medicine, Baylor Heart and Vascular Institute, Baylor University Medical Center at Dallas, Dallas, TX, USA.
    Introduction: Coronary chronic total occlusions (CTOs) are commonly encountered during diagnostic angiograms. With recent advances, especially in experienced centers, success rates with CTO percutaneous coronary intervention (PCI) have approached 80% or higher. It is important to note that despite these advancements in techniques, CTOs remain difficult to treat. Read More

    High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction.
    Cardiovasc Ther 2017 Oct;35(5)
    Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
    Aim: Although the gold standard treatment for acute myocardial infarction is reperfusion therapy, reperfusion itself can cause myocardial damage via induction of cardiac mitochondrial dysfunction. This can lead to increased myocardial infarct size, arrhythmias, and left ventricular (LV) dysfunction. Recently, a newly discovered peptide, Humanin, has been shown to exert several beneficial effects including antioxidative and antiapoptosis effects. Read More

    Cholinesterase inhibition reduces arrhythmias in asymptomatic Chagas disease.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Physiology and Pharmacology and Post-Graduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, Brazil.
    Introduction: Parasympathetic dysfunction may play a role in the genesis of arrhythmias in Chagas disease.

    Aim: This study evaluates the acute effects of pyridostigmine (PYR), a reversible cholinesterase inhibitor, on the occurrence of arrhythmias in patients with Chagas cardiac disease.

    Method: Following a double-blind, randomized, placebo-controlled, cross-over protocol, 17 patients (age 50±2 years) with Chagas cardiac disease type B underwent 24-hour Holter recordings after oral administration of either pyridostigmine bromide (45 mg, 3 times/day) or placebo (PLA). Read More

    Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
    Aim: We previously demonstrated that anoxia-mediated Ca(2+) handling dysfunction could be ameliorated through inhibition of mevalonate pathway via RhoA- and Ras-related mechanisms in H9c2 cells. In this study, we further explored whether inhibition of mevalonate pathway is associated with cardiac remodeling and dysfunction in ischemic cardiomyopathy, and discussed the possible role of Ras, Rac and RhoA in cardiac dysfunction.

    Methods: We investigated the role of mevalonate pathway in cardiac remodeling and cardiomyocyte Ca(2+) handling proteins expression in a rat model of cardiac dysfunction due to myocardial infarction (MI). Read More

    Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits.
    Cardiovasc Ther 2017 Oct;35(5)
    Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
    Background/aims: Recent evidence indicates that peroxisome proliferator-activated receptor (PPAR)-γ activators exert anti-inflammatory and antioxidant actions. However, the underlying mechanisms by which these agents prevent atrial remodeling in diabetes are not completely elucidated. We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits. Read More

    MiR-195 promotes abdominal aortic aneurysm media remodeling by targeting Smad3.
    Cardiovasc Ther 2017 Dec;35(6)
    Department of Cardiothoracic Surgery, Huaihe Hospital of Henan University, Kaifeng, China.
    Introduction: MiR-195 has been implicated in the development of abdominal aortic aneurysms (AAA). However, the underlying mechanisms have not been fully addressed.

    Aim: To explore the roles of miR-195 in regulating the proliferation and apoptosis of vascular smooth muscle cells (VSMCs), as well as its molecular basis in vitro. Read More

    Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
    Background: Chronic heart failure (CHF) involves fluid retention and volume overload, leading to impaired cardiac function. In these conditions, diuretic agents are most commonly used to treat edema and thereby reducing the volume load on the failing heart. There are several other beneficial effects of diuretics apart from their action on urinary excretion. Read More

    Pitavastatin up-regulates eNOS production by suppressing miR-155 expression in lipopolysaccharide-stimulated human umbilical vein endothelial cells.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, Henan, China.
    Aim: Pitavastatin (Pit) has been proved to efficiently inhibit the onset and progression of atherosclerosis. However, the mechanism by which Pit exerts nonlipid-related effects, such as antiinflammatory actions, is not quite clear. Our study aimed at investigating the effect of Pit on the expression of endothelial NO synthase (eNOS) and miR-155 in LPS-stimulated HUVECs to reveal the antiinflammatory mechanism of pitavastatin. Read More

    Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis.
    Cardiovasc Ther 2017 Dec;35(6)
    Department of Pharmacy, Integrated Research Institute of Pharmaceutical Sciences, and BK21 PLUS Team for Creative Leader Program for Pharmacomics-based Future Pharmacy, College of Pharmacy, The Catholic University of Korea, Bucheon-si, Gyeonggi-do, Korea.
    Aims: We have previously shown that the combination of pravastatin and sarpogrelate is synergistically beneficial for atherosclerosis. In this study, we investigated whether the pravastatin-sarpogrelate combination was sufficient for treatment in an old mouse model of atherosclerosis or if additional intervention would be needed to address the newly included aging factor and its complex pathophysiological impact on the atherosclerogenic state. We added an anti-TNF biological to the combination treatment cocktail because of the known pathologic roles of TNF in the aging process. Read More

    Postconditioning with metformin attenuates apoptotic events in cardiomyoblasts associated with ischemic reperfusion injury.
    Cardiovasc Ther 2017 Dec 20;35(6). Epub 2017 Oct 20.
    Department of Biochemistry, Kerala University, Thiruvananthapuram, Kerala, India.
    Aim: Ischemic postconditioning is considered as a potent method to combat ischemic reperfusion injury than preconditioning and rapid initiation of reperfusion with potent antioxidant compounds can be one of the most effective treatments to reduce the infarct size and behavioral deficits as a result of ischemic insult. The present study aims to determine the postconditioning effects of metformin in experimental ischemia.

    Methods: H9C2 cells were subjected to experimental ischemia and reperfused with metformin. Read More

    Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
    Introduction: Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies.

    Aims: We use observational long-term data on PAH patients treated with subcutaneous (SQ) treprostinil from a large open-label study. Read More

    Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.
    Cardiovasc Ther 2017 Oct;35(5)
    The Jilin Province People's Hospital, Changchun, China.
    Background: Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF).

    Objective: This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. Read More

    Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
    Cardiovasc Ther 2017 Oct;35(5)
    Global Product Development CVMET Therapeutics, Pfizer Inc, New York, NY, USA.
    Aim: To characterize the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of bococizumab, a monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), administered subcutaneously (s.c.) to the abdomen, thigh, or upper arm (NCT02043301). Read More

    Exploring the putative role of TRPV1 -dependent CGRP release in remote hind preconditioning-induced cardioprotection.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala, India.
    Background: Remote ischemic preconditioning (RIPC) is a phenomenon whereby transient nonlethal ischemia and reperfusion episodes confer protection against prolonged ischemia reperfusion-induced injury. However, the underlying intracellular signaling has not been extensively explored.

    Objective: This study aimed to inspect the putative involvement of TRPV1 -dependent CGRP release in mediating remote hind limb preconditioning-induced cardioprotection. Read More

    Effects of conjugated linoleic acid supplementation on serum C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.
    Cardiovasc Ther 2017 Dec;35(6)
    Division of Medical Education, Brighton and Sussex Medical School, Falmer, Brighton, UK.
    Aim: To undertake a systematic review and meta-analysis of prospective studies to determine the effect of conjugated linoleic acids (CLAs) supplementation on serum C-reactive protein (CRP).

    Method: PubMed-Medline, Web of Science, Cochrane Database, and Google Scholar databases were searched (up until May 2016) to identify prospective studies evaluating the impact of CLAs supplementation on serum CRP. Random-effects models meta-analysis was used for quantitative data synthesis. Read More

    Visit-to-visit systolic blood pressure variability predicts treatment-related adverse event of hyponatremia in SPRINT.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA.
    Hypertension is a common condition and an important cardiovascular risk factor. SPRINT trial showed that the beneficial effects of targeting systolic blood pressure <120 mm Hg were accompanied by more adverse events. De-identified SPRINT database was used for this analysis. Read More

    Endothelial damage effects of circulating microparticles from patients with stable angina are reduced by aspirin through ERK/p38 MAPKs pathways.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
    Introduction: Platelet activation participates in the development of both coronary artery disease (CAD) and circulating microparticles (MPs). As a commonly used medicine for coronary heart disease, whether aspirin affects the function of MPs remains unclear.

    Aims: This study was designed to test MPs from healthy subjects, and stable angina (SA) patients before and after aspirin administration were obtained. Read More

    Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
    The development of the promising agent sacubitril/valsartan, known as an angiotensin receptor blocker-neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may benefit morbidity, mortality, and readmission rates in patients with HF. The PARADIGM-HF trial demonstrated that the ARNI can reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), while ongoing PARAMOUNT and PARAGON-HF trials determined whether the ARNI has morbidity and mortality benefits in patients with heart failure with preserved ejection fraction (HFpEF). However, the risk of long-term side effects of the ARNI such as cognitive dysfunction or Alzheimer's disease (AD) remains unknown. Read More

    Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention: A large single-center data.
    Cardiovasc Ther 2017 Aug;35(4)
    Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.
    Background: Although numerous studies, to date, have demonstrated a specific phenomenon called the "obesity paradox" in patients after percutaneous coronary intervention (PCI), studies performed in China thus far have consistently shown an absence of this phenomenon.

    Hypothesis: "Obesity paradox" does exist in Chinese PCI patients.

    Methods: 10 724 consecutive Chinese patients who had undergone PCI treatment at a single center from January 2013 to December 2013 were prospectively recruited. Read More

    Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Cardiology, Patras University Hospital, Patras, Greece.
    Aims: Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients.

    Methods: In a prospective, observational, multicenter, cohort study, 2047 patients were recruited into the GReekAntiPlatElet (GRAPE) Registry and were followed up until 1 year for major adverse cardiovascular events (MACE, composite of death, nonfatal myocardial infarction, urgent revascularization, and stroke) and bleeding events (Bleeding Academic Research Consortium [BARC] classification). Read More

    The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall.
    Cardiovasc Ther 2017 Aug;35(4)
    Mechanical Engineering Department, University of South Alabama, Mobile, AL, USA.
    Aim: Nonstent drug delivery platforms have recently emerged as an alternative treatment of peripheral arterial disease. Perfusion catheters have the potential to directly deliver antiproliferative agents to the medial arterial layer to prevent restenosis. The purpose of this study was to therefore determine the effectiveness of a perfusion catheter to deliver paclitaxel, a proven antiproliferative agent, to combat restenosis. Read More

    Aspirin responsiveness changes in obese patients following bariatric surgery.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Pharmacy Practice, University at Buffalo School of Pharmacy & Pharmaceutical Sciences, Buffalo, NY, USA.
    Aims: Bariatric surgery has emerged as a promising treatment option for weight loss and to counter the metabolic consequences of obesity. Obesity has been linked to a hyperaggregable state, as well as a blunted response to aspirin. This pilot study assessed the hypothesis that bariatric surgery would lead to an improvement in aspirin-induced platelet inhibition and a reduction in platelet aggregability. Read More

    Assessment of vascular response to BiOSS LIM C(®) stents vs Orsiro(®) stents in the porcine coronary artery model.
    Cardiovasc Ther 2017 Aug;35(4)
    American Heart of Poland, Center for Cardiovascular Research and Development, Katowice, Poland.
    Aims: The optimal treatment strategy for coronary bifurcation lesions is still unknown. The aim of the study was to assess applicability of the new cobalt-chromium version of the sirolimus-eluting dedicated bifurcation BiOSS(®) LIM C stent in comparison with regular sirolimus-eluting Orsiro(®)  stent in a porcine coronary model.

    Methods: A total of 13 BiOSS(®) LIM C stents and 6 Orsiro(®) stents were implanted in normal nonatherosclerotic porcine straight coronary arteries of six animals using 1. Read More

    Pulmonary vein isolation with concomitant renal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: Data from implantable cardiac monitor.
    Cardiovasc Ther 2017 Aug;35(4)
    University of Rochester School of Medicine and Dentistry, New York, NY, USA.
    Background: Renal artery denervation (RDN) has provided incremental atrial fibrillation (AF) suppression after pulmonary vein isolation (PVI) in patients with AF in the setting of drug-resistant hypertension.

    Objective: To assess the relationship between changes of mean blood pressure (BP) and AF recurrences/AF burden after PVI combined with RDN.

    Methods: All patients from two randomized studies with symptomatic paroxysmal AF and/or persistent AF and resistant hypertension who underwent PVI-only (n=37) or PVI with RDN (n=39), and implantable cardiac monitor (ICM) implantation were eligible for this study. Read More

    Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction-"Expanding arena for ivabradine".
    Cardiovasc Ther 2017 Aug;35(4)
    Escorts Heart Hospital, New Delhi, India.
    Background: Atrioventricular (AV) blocks are of concern with the use of beta blockers in inferior wall myocardial infarction (MI). Ivabradine lowers heart rate with a lesser risk of AV blocks.

    Objectives: To compare ivabradine with metoprolol in acute inferior wall MI in terms of feasibility, tolerability, and efficacy. Read More

    RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Cardiovascular Medicine, St. Vincent Charity Medical Center, A Teaching Hospital of Case Western Reserve University, Cleveland, OH, USA.
    Low-density cholesterol (LDL) has been the prime target of currently available lipid-lowering therapies although current research is expanding the focus beyond LDL lowering and has included high-density cholesterol (HDL) also as the target. Bromo and extra-terminal (BET) proteins are implicated in the regulation of transcription of several regulatory genes and regulation of proinflammatory pathways. As atherosclerosis is an inflammatory pathway and studies showed that BET inhibition has a role in inhibiting inflammation, the concept of BET inhibition came in the field of atherosclerosis. Read More

    Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats.
    Cardiovasc Ther 2017 Aug;35(4)
    Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
    Aims: Comparative efficacy between fibroblast growth factor 21 (FGF21) and vildagliptin on metabolic regulation, cardiac mitochondrial function, heart rate variability (HRV), and left ventricular (LV) function is not known. We hypothesized that FGF21 and vildagliptin share a similar efficacy in improving these parameters in high fat diet (HFD)-induced obese-insulin resistant rats.

    Methods: Twenty-four male Wistar rats were fed with either a normal diet (ND) or a HFD for 12 weeks. Read More

    Epigenetic regulation in monocyte/macrophage: A key player during atherosclerosis.
    Cardiovasc Ther 2017 Jun;35(3)
    Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, China.
    Atherosclerosis is a chronic inflammatory disease. Recently, a growing body of evidence emphasizes that the monocyte and macrophage differentiation and activation are key processes in the development of atherosclerosis. However, the regulatory mechanism that manipulates the function of monocyte and macrophage is still unclear. Read More

    Percutaneous coronary intervention vs coronary artery bypass grafting for left main coronary artery disease? A systematic review and meta-analysis of randomized controlled trials.
    Cardiovasc Ther 2017 Jun;35(3)
    Division of Interventional Cardiology, Section of Cardiology, University of Connecticut, Farmington, CT, USA.
    Background: It is not clear whether percutaneous coronary intervention (PCI) is as effective and safe as coronary artery bypass grafting (CABG) for left main coronary artery disease. We aimed to perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) that compared PCI and CABG in left main coronary disease.

    Methods: We searched PubMed, EMBASE, Cochrane, Scopus and relevant references for RCTs (inception through, November 20, 2016 without language restrictions) and performed meta-analysis using random-effects model. Read More

    Effects of clopidogrel on inflammatory cytokines and adhesion molecules in human endothelial cells: Role of nitric oxide mediating pleiotropic effects.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
    Introduction: Clopidogrel is commonly used in prevention and treatment of atherothrombosis. Some previous studies have suggested a pleiotropic effect of clopidogrel; however, when this drug causes platelet-independent effects on endothelial function remains unclear.

    Aims: To evaluate the influence of clopidogrel on inflammatory biomarkers and adhesion molecules in human endothelial cells and the role of nitric oxide (NO) in this process. Read More

    Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.
    Cardiovasc Ther 2017 Jun;35(3)
    Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, CA, USA.
    Aim: We designed a study to evaluate the cardioprotective effect of two soluble epoxide hydrolase (sEH) inhibitors, 1-(1-propanoylpiperidin-4-yl)-3-(4-trifluoromethoxy)phenyl)urea (TPPU) and trans-4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]cyclohexyloxy}benzoic acid (t-TUCB), in ischemia-reperfusion (IR) model.

    Methods: Cardioprotective effects of the sEH inhibitors were evaluated against IR-induced myocardial damage in hearts from normal, hypertensive, and diabetic rats using Langendorff's apparatus. In addition, the effect of sEH inhibitors on endothelial function was evaluated in vitro and ex vivo using isolated rat thoracic aorta. Read More

    Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy.
    Cardiovasc Ther 2017 Jun;35(3)
    Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
    Introduction: Amiodarone is associated with significant long-lasting adverse drug reactions (ADRs). Guidelines recommend laboratory monitoring during long-term use. However, data of compliance with laboratory monitoring are lacking. Read More

    Remote physiological ischemic training promotes coronary angiogenesis via molecular and cellular mobilization after myocardial ischemia.
    Cardiovasc Ther 2017 Jun;35(3)
    Department of Neuro Rehabilitation Medicine, Beijing United Family Rehabilitation Hospital, Beijing, China.
    Aim: This study was designed to explore the mechanism of physiological ischemic training (PIT) on remote limbs, with a special focus on the potential role of endothelial progenitor cells (EPCs), vascular endothelial growth factor (VEGF), and nitric oxide (NO) in local ischemic myocardium.

    Method: Myocardial ischemia (MI) rabbit models were randomly assigned to sham-operated group (SO), training-only group (TO), MI group, PIT group, VEGF inhibitor group (VEGF-), NO inhibitor group (NO-), VEGF and NO inhibitor group (VEGF-/NO-), and EPC inhibitor group (EPC-). A constrictor was implanted around the left ventricular branch to induce controlled MI. Read More

    1 OF 12